- Home
- PAVS vs TLSA Comparison
PAVS vs TLSA Comparison
Compare PAVS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVS | TLSA |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 155.2M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PAVS | TLSA |
|---|---|---|
| Price | $1.93 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 24.1M | 145.5K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.73 |
| 52 Week High | $3.83 | $2.60 |
Technical Indicators
Market Signals| Indicator | PAVS | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 48.84 |
| Support Level | $0.60 | $1.27 |
| Resistance Level | $2.44 | $1.62 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 82.79 | 45.61 |
Price Performance
Historical ComparisonAbout PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.